FDA Brief

Warning letters Drugs

FDA warning letter to

The Tranzonic Companies/Innocore Sales & Marketing Inc.

High riskIssued Oct 16, 2025Posted Oct 28, 2025Center for Drug Evaluation and Research (CDER)

FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

What happened

FDA inspected Innocore Sales & Marketing's drug manufacturing facility in Woodstock, Ontario, Canada, from April 22 to 25, 2025, and found significant current good manufacturing practice (CGMP) violations for finished drugs. FDA said the company lacked adequate finished-product release testing, identity testing of incoming components at risk for diethylene glycol (DEG) and ethylene glycol (EG), an adequate stability program, and quality-unit oversight; it also noted similar observations in a June 2019 inspection. The company's May 16, 2025, response was inadequate, FDA said.

What FDA found

  1. The company did not adequately test each finished drug batch before release for identity and strength of the active ingredient and for objectionable microorganisms.

    21 CFR 211.165(a) and 211.165(b)
  2. The company did not perform an adequate identity test on each incoming lot of a component, including one at higher risk for diethylene glycol or ethylene glycol contamination.

    21 CFR 211.84(d)(1)
  3. The company lacked adequate stability data and storage to show its drug products keep their quality through the labeled expiry in the marketed container.

    21 CFR 211.166(a)
  4. The quality control unit did not ensure adequate cleaning and maintenance, batch records, and investigations with lasting corrective actions.

    21 CFR 211.22; 21 CFR 211.67(a); 21 CFR 211.188; 21 CFR 211.192

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrective actions and detailed plans for laboratory testing, component testing, stability, and quality-unit oversight; it also asks for DEG/EG test results from retained samples within 30 calendar days.

Who should pay attention

  • over-the-counter drug brands and retailers that use this contractor
  • suppliers of high-risk drug components such as glycerin
  • companies relying on supplier certificates of analysis for incoming ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk